+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nanoparticles Contract Manufacturing Market by Company Size, Type of Nanoparticle Manufactured, Scale of Operation, Type of End User, and Key Geographical Regions, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035

  • PDF Icon

    Report

  • 265 Pages
  • January 2022
  • Region: Global, Latin America
  • Roots Analysis
  • ID: 5531028

Overview


Over the past few decades, the pharmaceutical industry has witnessed significant growth, as also evident from the continuously growing pipeline of drug candidates that have been marketed or are being evaluated across several development stages. However, a recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are associated with concerns related to solubility/permeability. Further, it was observed that a pharmacological product became 10% less vigorous, each time, when mixed with another product, due to drug incompatibility.Therefore, players engaged in this domain are actively trying to identify ways to improve/augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, the use of nanoparticles has garnered the attention of many drug developers. In fact, the novel vaccines developed to treat COVID-19 are enclosed within a layer of lipid nanoparticles; these molecules assist the delivery of active ingredients to the required site of action. Moreover, many drug developers are using lipid/metal nanoparticles to re-formulate existing product candidates in order to further improve their bioavailability/biocompatibility. However, for some of the nanoparticles having medical applications, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges, such as need for specialized expertise (especially in case of lipid nanoparticles), lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. Considering the routine operations-related and technical challenges, an increased number of pharmaceutical companies have demonstrated the preferences to outsource their respective nanoparticle production operations to specialized service providers. 


There are numerous benefits of engaging contract development and manufacturing (CDMO)/contract manufacturing organizations (CMO) for nanoparticle manufacturing; for instance, contracting a supplier for medical grade nanoparticles enables sponsors to leverage new technologies (available with the service provider), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers and technology providers, who claim to have the required capabilities to manufacture nanoparticles (lipid and metal nanoparticles). However, the global expertise and capabilities necessary for the production of GMP grade nanoparticles are currently limited. As a result, many companies offering contract manufacturing services for nanoparticles are actively trying to consolidate their presence in this field, by entering into various strategic alliances to broaden their respective service portfolios. It is also worth highlight that, recently, a number of deals were inked between vaccine developers and CMOs in order to cater the urgent need for nanoparticle-based solutions for the development of COVID-19 vaccines. Given the benefits of using nanoparticles to improve drug-like properties, we believe, that the demand for high quality nanoparticles is likely to drive considerable growth within the specialty contract manufacturing market in the coming years.


Scope of the Report


The “Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size (Very Small Companies, Small Companies, Mid-Sized Companies, and Large Companies), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User (Educational Institutions, Pharmaceutical Companies, Research Institutions, and Other End Users), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA), Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035” report features an extensive study of contract service providers engaged in manufacturing of nanoparticles for the purpose of preclinical development, clinical research and commercialization. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain.


Amongst other elements, the report features:


  • A detailed overview of the current market landscape of nanoparticle contract manufacturers, along with information on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters, type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of manufacturing facilities, scale of operation (preclinical, clinical, and commercial), type of end user (educational institutions, pharmaceutical companies. research institutions, and other end users), type of service(s) offered, quality certifications and regulatory bodies. 
  • An in-depth analysis, highlighting the contemporary market trends using six schematic representations, including [A] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [B] a bubble representation based on company size and type of organization, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in this domain, [E] a 4D bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of service(s) offered), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and type of service(s) offered).
  • An in-depth company competitiveness analysis of nanoparticle contract manufacturers, based on several relevant parameters, such as company’s service strength (taking into consideration years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and type of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).
  • Elaborate profiles of key players that offer contract manufacturing services for nanoparticle(s). Each profile features a brief overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, recent developments and an informed future outlook.
  • An analysis of recent partnerships inked between various stakeholders engaged in this domain, during the period 2015-2021, based on several relevant parameters, such as year of partnership, type of partnership (company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements), type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement and regional distribution.
  • An insightful analysis, highlighting the various factors that need to be taken into consideration by nanoparticle(s) developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, and large), while taking the aforementioned decision.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the nanoparticle contract manufacturing market over the next fourteen years. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, over the period 2021-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world). In order to account for future uncertainties in the market and add robustness to our forecast model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. 


All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered


  • Who are the key players involved in nanoparticle contract manufacturing?
  • Which global regions are considered as key hubs for contract manufacturing of nanoparticles?
  • What are the most common services offered by nanoparticle contract manufacturers?
  • What type of partnership models are commonly adopted by stakeholders engaged in this industry?
  • Which factors are likely to influence the decision of nanoparticle manufacturing being done in-house or outsourced?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Introduction to Nanoparticles
3.2.1. Type of Nanoparticle(s)
3.3. Challenges Associated With Manufacturing of Nanoparticles
3.4 Overview of Contract Manufacturing
3.4.1 Commonly Outsourced Nanoparticle Manufacturing Operations
3.5. Advantages of Outsourcing Nanoparticle Manufacturing Operations
3.6. Key Considerations while Selecting a Contract Manufacturing Partner
3.7. Future Perspective


4. Market Landscape
4.1. Chapter Overview
4.2. Nanoparticle Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Organization
4.2.5. Analysis by Type of Nanoparticle(s) Manufactured
4.2.6. Analysis by Location of Manufacturing Facilities
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Type of End-user
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Quality Certifications
4.2.11. Analysis by Regulatory Bodies
4.2.12. Leading Nanoparticle Contract Manufacturers: Analysis by Number of Manufacturing Facilities


5. Key Insights
5.1. Chapter Overview
5.2. Analysis by Company Size and Type of Organization
5.3. Analysis by Company Size and Type of Nanoparticle(s) Manufactured
5.4. Analysis by Company Size and Scale of Operation
5.5. Analysis by Location of Headquarters (Country-Wise)
5.6. Analysis by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Services Offered (4D Bubble Representation)
5.7. Analysis by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End-user, Type of Service(s) Offered (Grid Representation)


6. Company Competitiveness Analysis
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Benchmarking of Service Strength
6.5. Benchmarking of Partnership Activity
6.6. Nanoparticle Contract Manufacturers: Company Competitiveness Analysis
6.6.1. Company Competitiveness Analysis: Very Small Companies
6.6.2. Company Competitiveness Analysis: Small Companies
6.6.3. Company Competitiveness Analysis: Mid-Sized Companies
6.6.4. Company Competitiveness Analysis: Large Companies


7. Company Profiles
7.1. Chapter Overview
7.2. Ardena
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook
7.3. Curia
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook
7.4. Corden Pharma
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook
7.5. Evonik
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook
7.6. Lsne Contract Manufacturing
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook
7.7. Polymun
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook
7.8. Technanoindia
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook


8. Partnerships and Collaborations
8.1. Chapter Overview
8.2. Partnership Models
8.3. Nanoparticle Contract Manufacturing: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Type of Nanoparticle(s) Manufactured
8.3.5. Emerging Focus Areas
8.3.6. Analysis by Seniority Level of Stakeholders
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. Region-Wise Distribution
8.3.8.2. Country-Wise Distribution


9. Outsourcing: Go / No-Go Framework
9.1. Chapter Overview
9.2. Assumptions and Parameter Definitions
9.3. Nanoparticle-Based Therapeutics Developers Outsourcing: Go / No-Go Framework
9.3.1. Scenario 1
9.3.2. Scenario 2
9.3.3. Scenario 3
9.3.4. Scenario 4
9.3.5. Scenario 5
9.4. Outsourcing: Go / No-Go Framework
9.4.1. Very Small Companies
9.4.2. Small Companies
9.4.3. Mid-Sized Companies
9.4.4. Large Companies
9.5. Concluding Remarks


10. Market Forecast and Opportunity Analysis
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Nanoparticle Contract Manufacturing Market, 2021-2035
10.4. Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
10.4.1. Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035
10.4.2. Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035
10.4.3. Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035
10.4.4. Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035
10.5. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
10.5.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035
10.5.2. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035
10.6. Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
10.6.1. Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035
10.6.2. Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035
10.6.3. Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035
10.7. Nanoparticle Contract Manufacturing Market: Distribution by Type of End-user, 2021 and 2035
10.7.1. Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035
10.7.2. Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035
10.7.3. Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035
10.7.4. Nanoparticle Contract Manufacturing Market for Other End-users, 2021-2035
10.8. Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
10.8.1. Nanoparticle Contract Manufacturing Market in North America, 2021-2035
10.8.2. Nanoparticle Contract Manufacturing Market in Europe, 2021-2035
10.8.3. Nanoparticle Contract Manufacturing Market in Asia, 2021-2035
10.8.4. Nanoparticle Contract Manufacturing Market in Mena, 2021-2035
10.8.5. Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035
10.8.6. Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035
10.9. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle and Region, 2021 and 2035
10.9.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035
10.9.2. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035
10.9.3. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035
10.9.4. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Mena, 2021-2035
10.9.5. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035
10.9.6. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035
10.9.7. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035
10.9.8. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035
10.9.9. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035
10.9.10. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Mena,2021-2035
10.9.11. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035
10.9.12. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035


11. Concluding Remarks
12. Executive Insights
12.1. Chapter Overview
12.2. Liposoma
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Asha Van Rooijen, Founder and Chief Executive Officer, Bart Metselaar, Director, Research and Development


13. Appendix I: Tabulated Data14. Appendix Ii: List of Companies and Organization
List of Figures
Figure 3.1 Application of Nanoparticles in Healthcare
Figure 3.2 Type of Nanoparticle(s) Based on Source of Material
Figure 3.3 Challenges Associated With Manufacturing of Nanoparticles
Figure 3.4 Type of the Third- Party Service Provider(s)
Figure 3.5 Commonly Outsourced Nanoparticle Manufacturing Operations
Figure 4.1 Nanoparticle Contract Manufactures: Distribution by Year of Establishment
Figure 4.2 Nanoparticle Contract Manufactures: Distribution by Company Size
Figure 4.3 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters
Figure 4.4 Nanoparticle Contract Manufactures: Distribution by Company Size and Location of Headquarters
Figure 4.5 Nanoparticle Contract Manufactures: Distribution by Type of Organization
Figure 4.6 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured
Figure 4.7 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters and Type of Nanoparticle(s) Manufactured
Figure 4.8 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters (Country-Wise) and Type of Nanoparticle(s) Manufactured
Figure 4.9 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of Nanoparticle(s) Manufactured
Figure 4.10 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility
Figure 4.11 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility (Country-Wise)
Figure 4.12 Nanoparticle Contract Manufactures: Distribution by Scale of Operation
Figure 4.13 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Scale of Operation
Figure 4.14 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Scale of Operation
Figure 4.15 Nanoparticle Contract Manufactures: Distribution by Type of End-user
Figure 4.16 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of End-user
Figure 4.17 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of End-user
Figure 4.18 Nanoparticle Contract Manufactures: Distribution by Type of Service(s) Offered
Figure 4.19 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of Service(s) Offered
Figure 4.20 Nanoparticle Contract Manufactures: Distribution by Quality Certifications
Figure 4.21 Nanoparticle Contract Manufactures: Distribution by Regulatory Bodies
Figure 4.22 Leading Nanoparticle Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Figure 5.1 Key Insights: Distribution by Company Size and Type of Organization
Figure 5.2 Key Insights: Distribution by Company Size and Type of Nanoparticle(s) Manufactured
Figure 5.3 Key Insights: Distribution by Company Size and Scale of Operation
Figure 5.4 Key Insights: Distribution by Location of Headquarters (Country-Wise)
Figure 5.5 4D Bubble Representation: Distribution by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Service(s) Offered
Figure 5.6 Grid Representation: Distribution by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End-user, and Type of Service(s) Offered
Figure 6.1 Nanoparticle Contract Manufacturers: Benchmarking of Service Strength
Figure 6.2 Nanoparticle Contract Manufacturers: Benchmarking of Partnership Activity
Figure 6.3 Company Competitiveness Analysis: Very Small Companies
Figure 6.4 Company Competitiveness Analysis: Small Companies
Figure 6.5 Company Competitiveness Analysis: Mid-Sized Companies
Figure 6.6 Company Competitiveness Analysis: Large Companies
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Nanoparticle(s) Manufactured
Figure 8.7 Partnerships and Collaborations: Emerging Focus Area
Figure 8.8 Partnerships and Collaborations: Distribution by Seniority Level of Stakeholders
Figure 8.9 Most Active Players: Distribution by Number of Partnerships
Figure 8.10 Partnerships and Collaborations: Distribution by Geography
Figure 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Outsourcing: Go / No-Go Framework
Figure 9.2 Outsourcing: Go / No-Go Framework: Benchmarking Leading Players
Figure 10.1 Global Nanoparticle Contract Manufacturing Market, 2021-2035 (Usd Billion)
Figure 10.2 Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
Figure 10.3 Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035 (Usd Billion)
Figure 10.4 Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035 (Usd Billion)
Figure 10.5 Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035 (Usd Billion)
Figure 10.6 Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035 (Usd Billion)
Figure 10.7 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
Figure 10.8 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035 (Usd Billion)
Figure 10.9 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035 (Usd Billion)
Figure 10.10 Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
Figure 10.11 Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035 (Usd Billion)
Figure 10.12 Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035 (Usd Billion)
Figure 10.13 Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035 (Usd Billion)
Figure 10.14 Nanoparticle Contract Manufacturing Market: Distribution by Type of End-user, 2021 and 2035
Figure 10.15 Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035 (Usd Billion)
Figure 10.16 Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035 (Usd Billion)
Figure 10.17 Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035 (Usd Billion)
Figure 10.18 Nanoparticle Contract Manufacturing Market for Other End-users, 2021-2035 (Usd Billion)
Figure 10.19 Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
Figure 10.20 Nanoparticle Contract Manufacturing Market in North America, 2021-2035 (Usd Billion)
Figure 10.21 Nanoparticle Contract Manufacturing Market in Europe, 2021-2035 (Usd Billion)
Figure 10.22 Nanoparticle Contract Manufacturing Market in Asia, 2021-2035 (Usd Billion)
Figure 10.23 Nanoparticle Contract Manufacturing Market in Mena, 2021-2035 (Usd Billion)
Figure 10.24 Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035 (Usd Billion)
Figure 10.25 Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035 (Usd Billion)
Figure 10.26 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured and Region, 2021 and 2035
Figure 10.27 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035 (Usd Billion)
Figure 10.28 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035 (Usd Billion)
Figure 10.29 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035 (Usd Billion)
Figure 10.30 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Mena, 2021-2035 (Usd Billion)
Figure 10.31 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035 (Usd Billion)
Figure 10.32 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035 (Usd Billion)
Figure 10.33 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035 (Usd Billion)
Figure 10.34 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035 (Usd Billion)
Figure 10.35 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035 (Usd Billion)
Figure 10.36 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Mena, 2021-2035 (Usd Billion)
Figure 10.37 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035 (Usd Billion)
Figure 10.38 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035 (Usd Billion)
Figure 12.1 Concluding Remarks: Market Landscape
Figure 12.2 Concluding Remarks: Partnerships and Collaborations
Figure 12.3 Concluding Remarks: Market Forecast


List of Tables
Table 3.1 Application of Nanoparticles in Healthcare
Table 3.2 Type of Nanoparticle(s) Based on Source of Material
Table 3.3 Challenges Associated With Manufacturing of Nanoparticles
Table 3.4 Type of the Third- Party Service Provider(s)
Table 3.5 Commonly Outsourced Nanoparticle Manufacturing Operations
Table 4.1 Nanoparticle Contract Manufactures: Distribution by Year of Establishment
Table 4.2 Nanoparticle Contract Manufactures: Distribution by Company Size
Table 4.3 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters
Table 4.4 Nanoparticle Contract Manufactures: Distribution by Company Size and Location of Headquarters
Table 4.5 Nanoparticle Contract Manufactures: Distribution by Type of Organization
Table 4.6 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured
Table 4.7 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters and Type of Nanoparticle(s) Manufactured
Table 4.8 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters (Country-Wise) and Type of Nanoparticle(s) Manufactured
Table 4.9 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of Nanoparticle(s) Manufactured
Table 4.10 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility
Table 4.11 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility (Country-Wise)
Table 4.12 Nanoparticle Contract Manufactures: Distribution by Scale of Operation
Table 4.13 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Scale of Operation
Table 4.14 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Scale of Operation
Table 4.15 Nanoparticle Contract Manufactures: Distribution by Type of End-user
Table 4.16 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of End-user
Table 4.17 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of End-user
Table 4.18 Nanoparticle Contract Manufactures: Distribution by Type of Service(s) Offered
Table 4.19 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of Service(s) Offered
Table 4.20 Nanoparticle Contract Manufactures: Distribution by Quality Certifications
Table 4.21 Nanoparticle Contract Manufactures: Distribution by Regulatory Bodies
Table 4.22 Leading Nanoparticle Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Table 5.1 Key Insights: Distribution by Company Size and Type of Organization
Table 5.2 Key Insights: Distribution by Company Size and Type of Nanoparticle(s) Manufactured
Table 5.3 Key Insights: Distribution by Company Size and Scale of Operation
Table 5.4 Key Insights: Distribution by Location of Headquarters (Country-Wise)
Table 5.5 4D Bubble Representation: Distribution by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Service(s) Offered
Table 5.6 Grid Representation: Distribution by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End-user, and Type of Service(s) Offered
Table 6.1 Nanoparticle Contract Manufacturers: Benchmarking of Service Strength
Table 6.2 Nanoparticle Contract Manufacturers: Benchmarking of Partnership Activity
Table 6.3 Company Competitiveness Analysis: Very Small Companies
Table 6.4 Company Competitiveness Analysis: Small Companies
Table 6.5 Company Competitiveness Analysis: Mid-Sized Companies
Table 6.6 Company Competitiveness Analysis: Large Companies
Table 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-2021
Table 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Table 8.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Table 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 8.6 Partnerships and Collaborations: Distribution by Type of Nanoparticle(s) Manufactured
Table 8.7 Partnerships and Collaborations: Emerging Focus Area
Table 8.8 Partnerships and Collaborations: Distribution by Seniority Level of Stakeholders
Table 8.9 Most Active Players: Distribution by Number of Partnerships
Table 8.10 Partnerships and Collaborations: Distribution by Geography
Table 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 9.1 Outsourcing: Go / No-Go Framework
Table 9.2 Outsourcing: Go / No-Go Framework: Benchmarking Leading Players
Table 10.1 Global Nanoparticle Contract Manufacturing Market, 2021-2035 (Usd Billion)
Table 10.2 Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
Table 10.3 Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035 (Usd Billion)
Table 10.4 Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035 (Usd Billion)
Table 10.5 Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035 (Usd Billion)
Table 10.6 Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035 (Usd Billion)
Table 10.7 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
Table 10.8 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035 (Usd Billion)
Table 10.9 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035 (Usd Billion)
Table 10.10 Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
Table 10.11 Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035 (Usd Billion)
Table 10.12 Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035 (Usd Billion)
Table 10.13 Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035 (Usd Billion)
Table 10.14 Nanoparticle Contract Manufacturing Market: Distribution by Type of End-user, 2021 and 2035
Table 10.15 Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035 (Usd Billion)
Table 10.16 Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035 (Usd Billion)
Table 10.17 Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035 (Usd Billion)
Table 10.18 Nanoparticle Contract Manufacturing Market for Other End-users, 2021-2035 (Usd Billion)
Table 10.19 Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
Table 10.20 Nanoparticle Contract Manufacturing Market in North America, 2021-2035 (Usd Billion)
Table 10.21 Nanoparticle Contract Manufacturing Market in Europe, 2021-2035 (Usd Billion)
Table 10.22 Nanoparticle Contract Manufacturing Market in Asia, 2021-2035 (Usd Billion)
Table 10.23 Nanoparticle Contract Manufacturing Market in Mena, 2021-2035 (Usd Billion)
Table 10.24 Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035 (Usd Billion)
Table 10.25 Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035 (Usd Billion)
Table 10.26 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured and Region, 2021 and 2035
Table 10.27 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035 (Usd Billion)
Table 10.28 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035 (Usd Billion)
Table 10.29 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035 (Usd Billion)
Table 10.30 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Mena, 2021-2035 (Usd Billion)
Table 10.31 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035 (Usd Billion)
Table 10.32 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035 (Usd Billion)
Table 10.33 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035 (Usd Billion)
Table 10.34 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035 (Usd Billion)
Table 10.35 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035 (Usd Billion)
Table 10.36 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Mena, 2021-2035 (Usd Billion)
Table 10.37 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035 (Usd Billion)
Table 10.38 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035 (Usd Billion)
Table 12.1 Concluding Remarks: Market Landscape
Table 12.2 Concluding Remarks: Partnerships and Collaborations
Table 12.3 Concluding Remarks: Market Forecast

Companies Mentioned

  • Ajinomoto Bio-Pharma Services
  • Alfa Aesar
  • Amplicon Biotech
  • Applied Chemical Works
  • Arcturus Therapeutics
  • Ardena
  • Ascendia Pharmaceuticals
  • AstraZeneca
  • AVANSA Technology & Services
  • Avanti Polar Lipids
  • Axolabs
  • BASF
  • BBI Group
  • BioNTech
  • BIOZOL Diagnostica
  • BOC Sciences
  • Caisson Biotech
  • Cal Nano
  • Cambridge Nanomaterials Technology
  • CanSinoBIO
  • Cayman Chemical
  • CONTRACTOR BUSINESS CENTER
  • Celonic
  • Center for Applied Nanotechnology
  • Cerion
  • ChemConnection 
  • CliniSciences
  • CordenPharma
  • Creative Biolabs
  • Croda
  • Crystallics
  • CureVac
  • Curia
  • CYBERNANO
  • Cytodiagnostics 
  • Daiichi Sankyo
  • Danaher
  • DCN Dx
  • Deakin University
  • Dolomite Microfluidics
  • E.M. Sullivan Associates
  • Eikonix
  • EMJapan
  • Encapsula NanoSciences
  • Entos
  • European Commission
  • Evonik
  • Exelead
  • Fortis Life Sciences
  • FUJIFILM Holdings 
  • GHO Capital
  • Howei Pharm
  • Hongwu International Group
  • i-DNA Biotechnology
  • Idifarma
  • Integrity Bio
  • Larodan
  • LEON
  • LIPOSOMA
  • LSNE Contract Manufacturing
  • Meliorum Technologies
  • Molchem Technologies UK
  • MyBiotech
  • Nagase Medicals
  • Nanochemazone
  • nanoComposix
  • Nanocs
  • NanoHybrids
  • NanoMaterials Technology
  • Nanomics Technologies 
  • Nanophase Technologies
  • Nanoshel
  • Nanostructured & Amorphous Materials
  • NARD Institute
  • NNCrystal
  • Novo Holdings
  • Nucleus Medical Media
  • NVIGEN
  • NYACOL® Nano Technologies
  • Ocean NanoTech
  • Osaka University
  • Permira
  • Pfizer
  • Pharmavize
  • Phosphorex
  • Polymun
  • Precision NanoSystems
  • Pró-Análise 
  • Prodotti Gianni
  • Santhiram Chemicals
  • Seashell Technology
  • Shionogi
  • Sirnaomics
  • SkySpring Nanomaterials
  • Stanipharm
  • Stratech Scientific
  • Strem 
  • Syntagon
  • T&T Scientific
  • TechNanoIndia
  • The Energy and Resources Institute (TERI)
  • U.S. Army
  • Vaxinano
  • Veritas Technologies
  • ZoneOne Pharma

Methodology

 

 

Loading
LOADING...